NCT04293276: Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer

NCT04293276
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic brain metastasis; Patients who have not received at least 1 line treatment in the past; Patients with a history of HER2 targeting tyrosine kinase inhibitors (e.g. Tukysa/tucatinib, Nerlynx/neratinib, Tykerb/lapatinib)
https://ClinicalTrials.gov/show/NCT04293276

Comments are closed.

Up ↑